Cargando…

Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer

The newly FDA-approved drug, Axitinib, is an effective therapy against RTKs, but it possesses severe adverse effects like hypertension, stomatitis, and dose-dependent toxicity. In order to ameliorate Axitinib’s downsides, the current study is expedited to search for energetically stable and optimize...

Descripción completa

Detalles Bibliográficos
Autores principales: Ejaz, Syeda Abida, Aziz, Mubashir, Fawzy Ramadan, Mohamed, Fayyaz, Ammara, Bilal, Muhammad Sajjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221949/
https://www.ncbi.nlm.nih.gov/pubmed/37241785
http://dx.doi.org/10.3390/molecules28104044
_version_ 1785049578988371968
author Ejaz, Syeda Abida
Aziz, Mubashir
Fawzy Ramadan, Mohamed
Fayyaz, Ammara
Bilal, Muhammad Sajjad
author_facet Ejaz, Syeda Abida
Aziz, Mubashir
Fawzy Ramadan, Mohamed
Fayyaz, Ammara
Bilal, Muhammad Sajjad
author_sort Ejaz, Syeda Abida
collection PubMed
description The newly FDA-approved drug, Axitinib, is an effective therapy against RTKs, but it possesses severe adverse effects like hypertension, stomatitis, and dose-dependent toxicity. In order to ameliorate Axitinib’s downsides, the current study is expedited to search for energetically stable and optimized pharmacophore features of 14 curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione) derivatives. The rationale behind the selection of curcumin derivatives is their reported anti-angiogenic and anti-cancer properties. Furthermore, they possessed a low molecular weight and a low toxicity profile. In the current investigation, the pharmacophore model-based drug design, facilitates the filtering of curcumin derivatives as VEGFR2 interfacial inhibitors. Initially, the Axitinib scaffold was used to build a pharmacophore query model against which curcumin derivatives were screened. Then, top hits from pharmacophore virtual screening were subjected to in-depth computational studies such as molecular docking, density functional theory (DFT) studies, molecular dynamics (MD) simulations, and ADMET property prediction. The findings of the current investigation revealed the substantial chemical reactivity of the compounds. Specifically, compounds S8, S11, and S14 produced potential molecular interactions against all four selected protein kinases. Docking scores of −41.48 and −29.88 kJ/mol for compounds S8 against VEGFR1 and VEGFR3, respectively, were excellent. Whereas compounds S11 and S14 demonstrated the highest inhibitory potential against ERBB and VEGFR2, with docking scores of −37.92 and −38.5 kJ/mol against ERBB and −41.2 and −46.5 kJ/mol against VEGFR-2, respectively. The results of the molecular docking studies were further correlated with the molecular dynamics simulation studies. Moreover, HYDE energy was calculated through SeeSAR analysis, and the safety profile of the compounds was predicted through ADME studies.
format Online
Article
Text
id pubmed-10221949
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102219492023-05-28 Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer Ejaz, Syeda Abida Aziz, Mubashir Fawzy Ramadan, Mohamed Fayyaz, Ammara Bilal, Muhammad Sajjad Molecules Article The newly FDA-approved drug, Axitinib, is an effective therapy against RTKs, but it possesses severe adverse effects like hypertension, stomatitis, and dose-dependent toxicity. In order to ameliorate Axitinib’s downsides, the current study is expedited to search for energetically stable and optimized pharmacophore features of 14 curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione) derivatives. The rationale behind the selection of curcumin derivatives is their reported anti-angiogenic and anti-cancer properties. Furthermore, they possessed a low molecular weight and a low toxicity profile. In the current investigation, the pharmacophore model-based drug design, facilitates the filtering of curcumin derivatives as VEGFR2 interfacial inhibitors. Initially, the Axitinib scaffold was used to build a pharmacophore query model against which curcumin derivatives were screened. Then, top hits from pharmacophore virtual screening were subjected to in-depth computational studies such as molecular docking, density functional theory (DFT) studies, molecular dynamics (MD) simulations, and ADMET property prediction. The findings of the current investigation revealed the substantial chemical reactivity of the compounds. Specifically, compounds S8, S11, and S14 produced potential molecular interactions against all four selected protein kinases. Docking scores of −41.48 and −29.88 kJ/mol for compounds S8 against VEGFR1 and VEGFR3, respectively, were excellent. Whereas compounds S11 and S14 demonstrated the highest inhibitory potential against ERBB and VEGFR2, with docking scores of −37.92 and −38.5 kJ/mol against ERBB and −41.2 and −46.5 kJ/mol against VEGFR-2, respectively. The results of the molecular docking studies were further correlated with the molecular dynamics simulation studies. Moreover, HYDE energy was calculated through SeeSAR analysis, and the safety profile of the compounds was predicted through ADME studies. MDPI 2023-05-12 /pmc/articles/PMC10221949/ /pubmed/37241785 http://dx.doi.org/10.3390/molecules28104044 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ejaz, Syeda Abida
Aziz, Mubashir
Fawzy Ramadan, Mohamed
Fayyaz, Ammara
Bilal, Muhammad Sajjad
Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
title Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
title_full Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
title_fullStr Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
title_full_unstemmed Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
title_short Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
title_sort pharmacophore-based virtual screening and in-silico explorations of biomolecules (curcumin derivatives) of curcuma longa as potential lead inhibitors of erbb and vegfr-2 for the treatment of colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221949/
https://www.ncbi.nlm.nih.gov/pubmed/37241785
http://dx.doi.org/10.3390/molecules28104044
work_keys_str_mv AT ejazsyedaabida pharmacophorebasedvirtualscreeningandinsilicoexplorationsofbiomoleculescurcuminderivativesofcurcumalongaaspotentialleadinhibitorsoferbbandvegfr2forthetreatmentofcolorectalcancer
AT azizmubashir pharmacophorebasedvirtualscreeningandinsilicoexplorationsofbiomoleculescurcuminderivativesofcurcumalongaaspotentialleadinhibitorsoferbbandvegfr2forthetreatmentofcolorectalcancer
AT fawzyramadanmohamed pharmacophorebasedvirtualscreeningandinsilicoexplorationsofbiomoleculescurcuminderivativesofcurcumalongaaspotentialleadinhibitorsoferbbandvegfr2forthetreatmentofcolorectalcancer
AT fayyazammara pharmacophorebasedvirtualscreeningandinsilicoexplorationsofbiomoleculescurcuminderivativesofcurcumalongaaspotentialleadinhibitorsoferbbandvegfr2forthetreatmentofcolorectalcancer
AT bilalmuhammadsajjad pharmacophorebasedvirtualscreeningandinsilicoexplorationsofbiomoleculescurcuminderivativesofcurcumalongaaspotentialleadinhibitorsoferbbandvegfr2forthetreatmentofcolorectalcancer